PURPOSE: To investigate the concentration and composition of N-glycans in plasma and vitreous samples obtained from patients with non-proliferative vitreoretinal diseases. METHODS: Plasma and vitreous samples were collected from 11 patients with idiopathic macular hole (MH) and 9 patients with epiretinal membrane (ERM). The samples were pretreated for enzymatic cleaving, and subsequently glycans released from proteins were captured on BlotGlyco H beads. Sialic acids were methyl-esterified. Processed glycans were tagged with aminooxy-functionalized peptide reagent (aoWR) and released from the beads, followed by detection by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). The concentration and composition of N-glycans in the samples were assessed. RESULTS: Concentration of N-glycans in vitreous samples (132 ± 29 pmol/100 μg protein) was significantly lower compared with those in plasma samples (714 ± 29 pmol/100 μg protein, p < 0.001). Predominant N-glycan in both plasma (39.7 ± 1.1 %) and vitreous fluid (37.2 ± 3.1 %) was identical, and the composition was presumed as [(Hex)2(HexNAc)2(NeuAc)2+ (Man)3(GlcNAc)2]. By contrast, the second-ranked N-glycan in vitreous samples (15.6 ± 1.5 %) was the seventh in plasma (2.3 ± 0.2 %). CONCLUSIONS: The current data provide useful information on N-glycan profile in the vitreous fluid, which is distinct from that in the plasma.
PURPOSE: To investigate the concentration and composition of N-glycans in plasma and vitreous samples obtained from patients with non-proliferative vitreoretinal diseases. METHODS: Plasma and vitreous samples were collected from 11 patients with idiopathic macular hole (MH) and 9 patients with epiretinal membrane (ERM). The samples were pretreated for enzymatic cleaving, and subsequently glycans released from proteins were captured on BlotGlyco H beads. Sialic acids were methyl-esterified. Processed glycans were tagged with aminooxy-functionalized peptide reagent (aoWR) and released from the beads, followed by detection by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). The concentration and composition of N-glycans in the samples were assessed. RESULTS: Concentration of N-glycans in vitreous samples (132 ± 29 pmol/100 μg protein) was significantly lower compared with those in plasma samples (714 ± 29 pmol/100 μg protein, p < 0.001). Predominant N-glycan in both plasma (39.7 ± 1.1 %) and vitreous fluid (37.2 ± 3.1 %) was identical, and the composition was presumed as [(Hex)2(HexNAc)2(NeuAc)2+ (Man)3(GlcNAc)2]. By contrast, the second-ranked N-glycan in vitreous samples (15.6 ± 1.5 %) was the seventh in plasma (2.3 ± 0.2 %). CONCLUSIONS: The current data provide useful information on N-glycan profile in the vitreous fluid, which is distinct from that in the plasma.
Authors: Y Wang; J Tan; M Sutton-Smith; D Ditto; M Panico; R M Campbell; N M Varki; J M Long; J Jaeken; S R Levinson; A Wynshaw-Boris; H R Morris; D Le; A Dell; H Schachter; J D Marth Journal: Glycobiology Date: 2001-12 Impact factor: 4.313
Authors: Ana Knezevic; Olga Gornik; Ozren Polasek; Maja Pucic; Irma Redzic; Mislav Novokmet; Pauline M Rudd; Alan F Wright; Harry Campbell; Igor Rudan; Gordan Lauc Journal: Glycobiology Date: 2010-03-30 Impact factor: 4.313
Authors: Eric C Seales; Gustavo A Jurado; Brian A Brunson; John K Wakefield; Andra R Frost; Susan L Bellis Journal: Cancer Res Date: 2005-06-01 Impact factor: 12.701
Authors: F Tanaka; Y Otake; T Nakagawa; Y Kawano; R Miyahara; M Li; K Yanagihara; J Nakayama; I Fujimoto; K Ikenaka; H Wada Journal: Cancer Res Date: 2000-06-01 Impact factor: 12.701